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Introduction

Results

Pain severity is an important symptom
to assess for in head and neck cancer
patients undergoing radiotherapy (RT)
due to its effects on the quality of life
[1]. Although radiation itself is painless,
it induces an acute postradiation
reaction that can cause many side
effects, with the most debilitating being
oral mucositis [2]. Studies have shown
a correlation between severity of pain
and severity of oral mucositis [3]. To
help manage the pain, the World
Health Organization (WHO) has a
recommended escalation chain of
analgesics guideline, starting with
NSAIDS, then weak opioids, followed
by potent opioids [4]. Due to the
subjective nature of pain, which can be
difficult for health systems to measure,
patient reported outcome measures
(PROMs) is a tool that can be used to
better gauge and improve patient’s
health experience [5]. Significant pain
signals that modifications in pain
management are needed to better
monitor the pain. In this study, we used
an institution-based PROM, The MD
Anderson Symptom Inventory
(MDASI), for pain assessment. The
objective of our project is to determine
the efficacy of pain management
during RT using PROM.

MDASI pain scores reported
during weekly see visits
revealed a significant increase
through the course of RT (p
<0.0001), with the highest
severity of pain is experienced
at the end of RT. Pain scores
were tested across age groups.
There were no significant
differences in pain scores
between age cohorts, with a
similar trend in each week
across the cohorts.

Fig. 1 Pain scores were compared to mucositis severity
(0 =none, 1 =mild, 2 =moderate, 3 =severe), assessed
weekly during radiation therapy visits.
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Future steps to take can include analyzing which
types of analgesics are given and at what point
during radiation therapy. Stronger pain medications
may be needed earlier during the course to prevent
high levels of pain seen towards the end of radiation
therapy. By analyzing pain scores alongside the type
and when analgesics are administered, this opens
the possibility for modification of the current pain
management plan, improving the patient’s overall
quality of life and experience.
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Fig. 3 MDASI pain scores measured
across weeks 1 to 7 for 5 age
cohorts. Patients were divided into
cohorts based on age (19-33 =1, 3448 =2, 49-64 =3, 65-78 =4, 79-98
=5).
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Weeks During RT

Retrospective data was obtained for
500 oral cavity and oropharyngeal
(OC/OPC) cancer patients, treated
with RT at theRadiation Oncology
department, MD Anderson Cancer
Center in Houston, TX, USA. Pain
scores were collected during the
weekly see visits using MDASI,
which is a multi-symptom PROM
used to assess the severity of
symptoms and how much of that
disrupts daily life [6], using a scale
from 0 to 10 (0 = no pain, 10=the
worst pain). Clinical data was
collected using EPIC and Brocade
software. Pain scores were
compared to mucositis intensity (0
=none, 1 =mild, 2 =moderate, 3
=severe), assessed weekly during
radiation therapy visits. Patients
were divided into cohorts based on
age (19-33 =1, 34-48 =2, 49-64 =3,
65-78 =4, 79-98 =5). T-test and
ANOVA test were used for
statistical analysis.

Fig. 2 MDASI pain scores and
mucositis severity displayed a
significant difference from week 1 to
week 7 of RT. (p <0.0001).

Pain Medication Types

Fig. 4 Collected the types of analgesics administered (based
on the WHO analgesics ladder) to 224 out of the 500 patients
during the course of RT. 0=no and 1=yes. The mean values for
each analgesic is displayed.

The aim of this study is to
determine the efficacy of pain
management during radiation
therapy using PROM. Our data
suggests that pain levels
consistently increased during
RT. This suggests the pain
management currently
implemented may not
adequately control pain during
the weeks of RT and may be in
need for improvement. This is
important to address due to the
negative effect pain can have on
the quality of life [1].
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